liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years
Public Health Agency Sweden, Sweden; Sahlgrens University Hospital, Sweden; Gothenburg University, Sweden.
Public Health Agency Sweden, Sweden.
Public Health Agency Sweden, Sweden.
Public Health Agency Sweden, Sweden.
Show others and affiliations
2015 (English)In: Vaccine, ISSN 0264-410X, E-ISSN 1873-2518, Vol. 33, no 31, 3717-3725 p.Article in journal (Refereed) Published
Abstract [en]

Prior study children from a DTaP efficacy trial were recruited at ages 5 and 15 years to randomized booster trials addressing immunogenicity and reactogenicity; 475 preschool children received mixed or separate injections of a reduced antigen vaccine (Tdap5, Sanofi Pasteur MSD) and an inactivated polio vaccine, and 230 adolescents received the same or another booster vaccine (Tdap1, SSI, Denmark). Pre-vaccination antibody concentrations against pertussis antigens were significantly higher at 15 than 5 years of age, probably due to natural boosting between the studies. Tdap5 induced comparable anti-PT concentrations at both ages, but antibody responses were significantly higher to filamentous haemagglutinin, pertactin and fimbriae 2/3 in adolescents. As expected, a higher amount of PT (Tdap1, 20 mu g) induced a stronger anti-PT response than a lower amount (Tdap5, 2.5 mu g). The frequency of adverse events was low and there were no serious adverse reactions. All local reactions had an early onset and a short duration. A large swelling or redness of more than half of the upper arm circumference was reported in 8/475 5-year-olds and in 6/230 15-year-olds. Children vaccinated with Tdap5 reported more moderate pain in adolescence than at preschool age, whereas itching was only reported in preschool children. Sweden introduced DTaP vaccines in 1996 after a 17-year hiatus with no general pertussis vaccination and pertussis was still endemic at the time of the studies. The frequency of adverse events was nevertheless low in both preschool children and adolescents and antibody responses were adequate. These studies document immunogenicity and reactogenicity in a trial cohort consecutively vaccinated with acellular pertussis vaccines from infancy to adolescence. (C) 2015 Elsevier Ltd. All rights reserved.

Place, publisher, year, edition, pages
Elsevier , 2015. Vol. 33, no 31, 3717-3725 p.
Keyword [en]
Pertussis; Diphtheria; Tetanus; Vaccine; Acellular; Booster; Preschool; Adolescent; Immunization; Immunogenicity; Adverse effect; Reactogenicity
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-120448DOI: 10.1016/j.vaccine.2015.05.079ISI: 000358096000018PubMedID: 26057135OAI: oai:DiVA.org:liu-120448DiVA: diva2:845685
Note

Funding Agencies|Aventis Pasteur Limited, Toronto, Canada; Aventis Pasteur MSD A/S, Copenhagen, Denmark; Sanofi Pasteur MSD Sweden; Statens Serum Institut (SSI) Denmark

Available from: 2015-08-12 Created: 2015-08-11 Last updated: 2015-08-12

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Nilsson, Lennart
By organisation
Division of Neuro and Inflammation ScienceAllergy CenterFaculty of Medicine and Health Sciences
In the same journal
Vaccine
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 66 hits
ReferencesLink to record
Permanent link

Direct link